Status
INACTIVE
Global HQ
New York, United States
Countries of investment
- USA
Investment stages
- Seed
Industries
- Biotechnology
- Health Tech
- AI
About
EpiGentek is a premier developer of cutting-edge technologies and products tailored for epigenetic research. Our extensive portfolio encompasses a wide range of assay kits, antibodies, proteins, and reagents, all meticulously crafted to enhance drug discovery and therapeutic development. Committed to advancing scientific understanding, EpiGentek empowers researchers with high-quality tools that facilitate groundbreaking discoveries in the field of epigenetics. Through our dedication to innovation and excellence, we strive to support the scientific community in unraveling the complexities of gene regulation and its implications in health and disease.
EpiGentek is a premier developer of cutting-edge technologies and products tailored for epigenetic research. Our extensive portfolio encompasses a wide range of assay kits, antibodies, proteins, and reagents, all meticulously crafted to enhance drug discovery and therapeutic development. Committed to advancing scientific understanding, EpiGentek empowers researchers with high-quality tools that facilitate groundbreaking discoveries in the field of epigenetics. Through our dedication to innovation and excellence, we strive to support the scientific community in unraveling the complexities of gene regulation and its implications in health and disease.
Investment Thesis
EpiGentek focuses on providing innovative and comprehensive solutions for epigenetic research, including DNA methylation, histone modification, and chromatin studies. Their goal is to support advancements in understanding epigenetics and its implications in various diseases, particularly cancer.
Manager's Experience
With a robust background in venture capital, the fund manager has successfully led over 30 deals across technology and healthcare sectors. His strategic approach combines data-driven insights with an operator-first philosophy, emphasizing early-stage investments. Active in both North America and Europe, he has facilitated notable exits that showcase his adeptness in identifying high-potential opportunities. This unique blend of experience and focus on thematic trends positions him as a significant player in the investment landscape.